Graf Acquisition Corp. IV (GFOR) Announces LOI with NKGen Biotech
by Nicholas Alan Clayton on 2023-03-24 at 7:05am

Graf Acquisition Corp. IV (NYSE:GFOR) announced that it has signed a non-binding letter of intent to combine with clinical-stage biopharma company NKGen.

This announcement is not a pure teaser as Graf IV is not facing an imminent extension vote and currently has until May 25 on its clock. It does, however, signal something of a shift for a team that has focused on other technology sectors in its past deals.

Santa Ana, California-based NKGen has five pharmaceutical formulas that have each reached some stage of Phase I and Phase II clinical trials seeking potential therapies for cancer and neurodegenerative conditions like Parkinson’s and Alzheimer’s.

Its only active trial is a Phase I study of its SNK01-US01 candidate that attempts to use autologous natural killer cells to reduce advanced solid tumors in adults, according to its website.

Graf IV CEO James Graf served as an officer in several of the Eagle team SPACs before going solo with Graf Industrial, which combined with Velodyne Lidar in September 2020. Graf II and III ultimately withdrew their registration statements, but mentioned “mobility, technology [and] transportation” as their first target sectors.

The SPAC aims to release additional details about the transaction once a definitive agreement is reached, and Graf IV will remain in SPACInsider‘s “Searching” column until then.

Recent Posts
by Kristi Marvin on 2024-06-15 at 11:30am

Terms Tracker for the Week Ending June 14, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. It was all about the new IPOs and new SPACs getting filed again this week. Cantor managed to price one new IPO on Monday night...

by Nicholas Alan Clayton on 2024-06-14 at 1:20pm

Launch One (NASDAQ:LPAAU) has continued Cantor Fitzgerald’s streak of underwriting new SPAC S-1s with nearly its whole offering already spoken for by non-managing sponsors, in this case a $200 million IPO to hunt in the Life Sciences industry. This SPAC’s non-managing sponsors have expressed interest in 22,690,820 of its units (assuming the full over-allotment option...

by Nicholas Alan Clayton on 2024-06-14 at 8:35am

At the SPAC of Dawn June is now on pace to more than double the issuance of new SPACs with its fifth filed yesterday while May saw seven new SPACs filed. Overall, there have been 21 new S-1 filings on the year and 12 IPOs. By comparison, there had been just 13 new SPACs filed...

by Nicholas Alan Clayton on 2024-06-13 at 12:39pm

After years of ratcheting up financial incentives to make and buy EVs, the world’s trade blocks are now rushing to stack up protectionist barriers, leaving the recent string of EV de-SPACs divided between them. Hong Kong-based EV maker Thunder Power may be the latest to join this increasingly complicated sector as Feutune Light (NASDAQ:FLVF) shareholders...

by Nicholas Alan Clayton on 2024-06-13 at 8:40am

At the SPAC of Dawn No news is good news appears to be the SPAC takeaway from CPI and Fed comments double-header yesterday. With inflation steady and one rate cut still expected for 2024, SPACs and de-SPACs in volatile sectors may now have a somewhat clearer flight path through the rest of the year. Fashion...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved